Gene therapy for hypertension: sense and antisense strategies

Bibliography

• KAPLAN NM: Clinical hypertension. Williams and Williams, Baltimore, (1998).
   Google Scholar
• LIFTON RP: Molecular genetics of human blood pressure variation. Science (1996) 272:676–680.
   PubMed Web of Science ®Google Scholar
• GYURKO R, WIELBO D, PHILLIPS MI:Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Reg. Pep. (1993) 49(2):167–174.
   PubMed Web of Science ®Google Scholar
• ••The first report of antisense inhibition in reducing hypertension.
   Google Scholar
• PHILLIPS MI, WIELBO D, GYURKO R: Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Intl. (1994) 46:1554–1556.
   PubMed Web of Science ®Google Scholar
• CHAO J, CHAO L: Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology (1997) 36(2-3):229–236.
   PubMedGoogle Scholar
• •The first report of the vasodilator gene approach to reducing hypertension.
   Google Scholar
• LIN KF, CHAO J, CHAO L: Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum. Gene Ther (1998) 9:1429–1438.
   PubMed Web of Science ®Google Scholar
• CHAO J, JIM L, LIN KF, CHAO L: Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens. Res. (1997) 20:2692–2677.
   Google Scholar
• LIN KF, CHAO L, CHAO J: Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension (1997) 30:307–313.
   PubMed Web of Science ®Google Scholar
• DOBRZYNSKI E, YOSHIDA H, CHAO J, CHAO L: Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunapharmacology (1999) 44:57–65.
   PubMedGoogle Scholar
• ZHANG YC, BUT JD, SHEN LP PHILLIPS MI: Antisense inhibition of Beta-l-Adrenoceptor mRNA in a single dose produces and profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation (2000) 101:682–688.
   PubMed Web of Science ®Google Scholar
• •Shows the effectiveness of AS-ODN in lowering blood pressure for up to one month with a single injection.
   Google Scholar
• ZHANG Y-C, KIMURA B, SHEN L, PHILLIPS MI: New13-blocker: prolonged reduction in high blood pressure with 13i antisense oligodeoxynucleotides. Hypertension (2000) 35(2):219–224.
   PubMedGoogle Scholar
• JEUNEMAITRE X, SOUBRIER F, KOTELEVETSEV YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell (1992) 71:169–180.
   PubMed Web of Science ®Google Scholar
• WIELBO D, SIMON A, PHILLIPS MI, TOFFOLO S: Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension (1996) 28:147–151.
   PubMed Web of Science ®Google Scholar
• MAKINO K, SUGANO M, OHTSUKA S, SAWADA S: Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension (1998) 31:1166–1170.
   PubMed Web of Science ®Google Scholar
• GYURKO R, TRAN D, PHILLIPS MI: Time course of inhibition of hypertension by antisense oligonucleotides targeted to ATI angiotensin receptor mRNA in spontaneously hypertensive rats. Am. Hypertension (1997) 10:56S–62S.
   Google Scholar
• KAGIYAMA S, VARELA A, PHILLIPS MI, GALLI SM: Antisense inhibition of brain renin angiotensin system decreased blood pressure in chronic 2K-1C hypertensive rats. Hypertension( 2001).
   Google Scholar
• PENG J-F, KIMURA B, FREGLY MJ, PHILLIPS MI: Reduction of cold-induced hypertension by antisenense oligodeoxynucleotides to angiotensinogen mRNA and ATI receptor mRNA in brain and blood. Hypertension (1998) 31:1317–1323.
   PubMed Web of Science ®Google Scholar
• LI B, HUGHES JA, PHILLIPS MI: Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem. Intl. (1996) 31(3):393–403.
   Web of Science ®Google Scholar
• •The report establishes basic data on cellular uptake of AS-ODNs.
   Google Scholar
• CROOKE ST: Progress in antisense technology: the end of the beginning. Methods Erizym. (2000) 313(1):3–45.
   PubMedGoogle Scholar
• WU P, PHILLIPS MI, BUI J, TERWILLINGER EF: Adeno-associated viral vector mediated transgene integration in nondividing cells. j Viral. (1998) 72(7):5919–5926.
   PubMed Web of Science ®Google Scholar
• TANG X, MOHUCZY D, ZHANG CY, KIMURA B, GALLI SM, PHILLIPS MI: Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. Am. J Physial. (1999) 277(6 Pt. 2):H2392–H2399.
   Google Scholar
• LYNCH KR, SIMNAD VI, BEN ARI ET, GARRISON JC: Localization of preangiotensinogen messenger RNA sequences in the rat brain. Hypertension (1986) 8:540–543.
   PubMed Web of Science ®Google Scholar
• ZOLOTUKHIN S, POTTER M, HAUSWIRTH WW, GUY J, MUZYCZKA NA: "Humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. I Viral. (1996) 70:4646–4654.
   Google Scholar
• MOHUCZY D, GELBAND C, PHILLIPS MI: Antisense inhibition of AT1 receptors in vascular smooth muscle cells using adeno-associated virus-based vector. Hypertension (1999) 33:354–359.
   PubMed Web of Science ®Google Scholar
• •Shows uptake and effectiveness of AS- DNA delivered by AAV.
   Google Scholar
• PHILLIPS MI: Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension (1997) 29:177–187.
   PubMed Web of Science ®Google Scholar
• KIMURA B, MOHUCZY D, TANG X, PHILLIPS MI: Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension ( 2001) 37(2):376–380.
   PubMed Web of Science ®Google Scholar
• IYER SN, LU D, KATOVICH M, RAIZADA MK: Chronic control of high blood pressure in the spontaneously hypertensive rats by delivery of angiotensin type 1 receptor antisense. Proc. Nati Acad. Li. USA (1996) 93:9960–9965.
   PubMed Web of Science ®Google Scholar
• PHILLIPS MI, KIMURA B, ZHANG Y-C, GELBAND CH: Gene therapy for hypertension: recombinant adeno-associated virus vector delivery of angiotensin type 1 receptor antisense in hypertensive double transgenic mice. Hypertension (2000) 36(4):P204.
   Google Scholar
• CHAMPION HC, BIVALACQUA TJ, TOYODA K, HEISTAD DD, HYMAN AL, KADOWITZ PJ: In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation (2000) 101(8):923–930.
   PubMed Web of Science ®Google Scholar
• REAVES PY, GELBAND CH, WANG H et al. Permanent prevention of hypertension by angiotensin II type 1 receptor antisense gene therapy. Circ. Res. (1999) 86:E44–E50.
   Google Scholar
• PHILLIPS MI: Is gene therapy for hypertension possible? Hypertension (1999) 33:8–13.
   PubMed Web of Science ®Google Scholar